The continued selloff is most likely because of what is already known to the market:
- McPhilly's is likely going to be dead on arrival, capex figure far too burdensome (especially given RRL's existing debt)
- With their long-promoted growth project likely gone, they're now having to pump Duketon North/South and Rosemont as "Underground Growth" whereas in reality it's just replacing depleted ounces.
- The announcement didn't give any specifics and just ambiguously claimed that the spend would be "value accretive across a range of prices". This from the same management team who decided to wait until gold was hitting fresh ATH's before closing out their hedge book at a cost of $98M - not sure they understand what "value" looks like
It's no surprise to me that since 1st May, short positions have increased from 1.22% up to 3.27%. If you wanted to hedge your long-gold positions elsewhere with a sector underperformer, Regis is where you come.
- Forums
- ASX - By Stock
- RRL
- Ann: Becoming a substantial holder
RRL
regis resources limited
Add to My Watchlist
1.72%
!
$4.56

Ann: Becoming a substantial holder, page-29
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.56 |
Change
-0.080(1.72%) |
Mkt cap ! $3.444B |
Open | High | Low | Value | Volume |
$4.60 | $4.63 | $4.51 | $17.87M | 3.932M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 26148 | $4.51 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.57 | 17051 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16 | 4.650 |
2 | 849 | 4.630 |
1 | 795 | 4.610 |
2 | 3001 | 4.590 |
1 | 110 | 4.560 |
Price($) | Vol. | No. |
---|---|---|
4.200 | 7075 | 1 |
4.280 | 77 | 2 |
4.550 | 350 | 1 |
4.560 | 12411 | 2 |
4.580 | 16000 | 2 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
RRL (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online